We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 674.00 | 5.94% | 12,026.00 | 12,006.00 | 12,012.00 | 12,096.00 | 11,850.00 | 11,890.00 | 4,650,557 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
From Apr 2019 to Apr 2024
By Razak Musah Baba
LONDON--AstraZeneca PLC's (AZN.LN) lung cancer drug Tagrisso has been granted full approval by the U.S. Food and Drug Administration.
AstraZeneca said Friday that the FDA has granted approval for Tagrisso (osimertinib) 80 milligram once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
Tagrisso is the first and only approved medicine in the U.S.
Also Friday, the biopharmaceutical said it has completed the agreement with TerSera Therapeutics LLC for the commercial rights to Zoladex in the U.S. and Canada.
In February AstraZeneca announced a deal giving TerSera commercial rights to its prostate cancer treatment Zoladex in the U.S. and Canada.
AstraZeneca said Friday it has received a payment of $250 million from TerSera for the commercial rights to the medicine.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
March 31, 2017 02:31 ET (06:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
